These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38893720)

  • 1. Sodium-Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction.
    Asakura-Kinoshita M; Masuda T; Oka K; Ohara K; Miura M; Morinari M; Misawa K; Miyazawa Y; Akimoto T; Shimada K; Nagata D
    Diagnostics (Basel); 2024 Jun; 14(11):. PubMed ID: 38893720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.
    Masuda T; Ohara K; Vallon V; Nagata D
    Am J Physiol Renal Physiol; 2022 Sep; 323(3):F361-F369. PubMed ID: 35900341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial.
    Oka K; Masuda T; Ohara K; Miura M; Morinari M; Misawa K; Miyazawa Y; Akimoto T; Shimada K; Nagata D
    Front Med (Lausanne); 2023; 10():1287066. PubMed ID: 38155663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study.
    Berton AM; Parasiliti-Caprino M; Prencipe N; Bioletto F; Lopez C; Bona C; Caputo M; Rumbolo F; Ponzetto F; Settanni F; Gasco V; Mengozzi G; Ghigo E; Grottoli S; Maccario M; Benso AS
    Front Neurosci; 2023; 17():1098404. PubMed ID: 37021137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
    Hallow KM; Helmlinger G; Greasley PJ; McMurray JJV; Boulton DW
    Diabetes Obes Metab; 2018 Mar; 20(3):479-487. PubMed ID: 29024278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
    Ohara K; Masuda T; Morinari M; Okada M; Miki A; Nakagawa S; Murakami T; Oka K; Asakura M; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Nagata D
    Diabetol Metab Syndr; 2020; 12():37. PubMed ID: 32377235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    Marton A; Saffari SE; Rauh M; Sun RN; Nagel AM; Linz P; Lim TT; Takase-Minegishi K; Pajarillaga A; Saw S; Morisawa N; Yam WK; Minegishi S; Totman JJ; Teo S; Teo LLY; Ng CT; Kitada K; Wild J; Kovalik JP; Luft FC; Greasley PJ; Chin CWL; Sim DKL; Titze J
    J Am Coll Cardiol; 2024 Apr; 83(15):1386-1398. PubMed ID: 38599715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
    Christ M; Ludwig N; Maisch B
    Herz; 2002 Mar; 27(2):135-49. PubMed ID: 12025459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.
    Lytvyn Y; Bjornstad P; Katz A; Singh SK; Godoy LC; Chung LT; Vinovskis CL; Pyle L; Roussel R; Perkins BA; Cherney D
    Diabetes Metab; 2020 Jun; 46(3):203-209. PubMed ID: 31816431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
    Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure.
    Kimura G
    Circ J; 2016 Oct; 80(11):2277-2281. PubMed ID: 27599528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure.
    Packer M
    Cardiovasc Diabetol; 2023 Aug; 22(1):197. PubMed ID: 37533009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Loop Diuretic Dosing Following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure.
    Trudeau BM; Allen LA; Billups SJ; Saseen JJ; Pearson SM
    J Pharm Pract; 2023 Dec; 36(6):1330-1335. PubMed ID: 35848505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.